Letters to the Editor

Cancer Risk Should Prompt Hepatitis B Surveillance for Patients

 


FREE PREVIEW. AAFP members and paid subscribers: Log in to get free access. All others: Purchase online access.


FREE PREVIEW. Purchase online access to read the full version of this article.

Am Fam Physician. 2015 Mar 1;91(5):279.

Original article: Challenges and Opportunities in the Care of Asian American Patients

Issue date: October 1, 2014

Available online at: http://www.aafp.org/afp/2014/1001/p490.html

to the editor: With regard to the case scenario posed in this article, I would like to comment as a family physician with an interest in the care of patients with hepatitis B. Although we should be circumspect about using scare tactics with our patients, I believe that one should emphasize the need for surveillance for cirrhosis and hepatoma in a 48-year-old male immigrant with chronic hepatitis B. To this end, I believe it is fair to emphasize the word cancer—a diagnosis fraught with fear and foreboding regardless of one's ethnicity or cultural identity.

Although the patient in the case scenario may not need antiviral treatment now, he should be informed that if future testing reveals that the hepatitis B has begun to cause hepatocellular damage, oral antiviral treatment is available, and that such treatment will decrease the likelihood of progression to cirrhosis and hepatoma.

As an aside, complete blood counts are justified to evaluate liver health. I have found that many such complete blood counts reveal eosinophilia. The main parasite for which to search in such cases is Strongyloides stercoralis, which can persist in immigrants because of its multiorgan life cycle. In many immigrants from Asia whom I have evaluated for hepatitis B, I have diagnosed Strongyloides infection via immunoglobulin G by enzyme-linked immunosorbent assay—easily treated with ivermectin. As Dr. Nguyen notes, many screening tests and preventive services can be completed with a simple blood draw, as in the case of Strongyloides, for which serologic testing is better than stool sampling.

Author disclosure: Dr. Yamada has served on an advisory board for Gilead.

Send letters to Kenneth W. Lin, MD, MPH, Associate Deputy Editor for AFP Online, e-mail: afplet@aafp.org, or 11400 Tomahawk Creek Pkwy., Leawood, KS 66211-2680.

Please include your complete address, e-mail address, and telephone number. Letters should be fewer than 400 words and limited to six references, one table or figure, and three authors.

Letters submitted for publication in AFP must not be submitted to any other publication. Possible conflicts of interest must be disclosed at time of submission. Submission of a letter will be construed as granting the American Academy of Family Physicians permission to publish the letter in any of its publications in any form. The editors may edit letters to meet style and space requirements.



 

Copyright © 2015 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


MOST RECENT ISSUE


Sep 15, 2016

Access the latest issue of American Family Physician

Read the Issue


Email Alerts

Don't miss a single issue. Sign up for the free AFP email table of contents.

Sign Up Now

Navigate this Article